BioSpace News Archive

Aileron Therapeutics, Inc. will host a virtual key opinion leader event from 4:30 to 5:30 p.m. ET titled “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” featuring pulmonary care experts Fernando J. Martinez, M.D., M.S. from Weill Cornell Medicine; Tejaswini Kulkarni, M.D., M.P.H. from University of Alabama at Birmingham Medicine; and Andreas Günther, M.D. from Agaplesion Evang.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.

Relay Therapeutics, Inc. will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024.

NeuroPace, Inc. announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024.

PacBio announced financial results for the quarter and fiscal year ended December 31, 2023.

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, reported financial results for the fourth quarter and full year 2023.

Corcept Therapeutics Incorporated reported its results for the quarter and year ended December 31, 2023.

Ocuphire Pharma, Inc. announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to Ashwath Jayagopal, Ph.D., M.B.A., the Company’s newly appointed Chief Scientific and Development Officer and to Nirav Jhaveri, C.F.A., M.B.A., the Company’s newly appointed Chief Financial Officer in connection with their employment with the Company effective on February 12, 2024.

CooperCompanies announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol “COO”.

BD, a leading global medical technology company, announced that it will present at the following healthcare conferences.